Last reviewed · How we verify
Gemcitabine alone
Gemcitabine is a nucleoside analog that inhibits ribonucleotide reductase and gets incorporated into DNA, causing chain termination and cell death.
Gemcitabine is a nucleoside analog that inhibits ribonucleotide reductase and gets incorporated into DNA, causing chain termination and cell death. Used for Non-small cell lung cancer, Pancreatic cancer, Bladder cancer.
At a glance
| Generic name | Gemcitabine alone |
|---|---|
| Also known as | Gemzar |
| Sponsor | Intergroupe Francophone de Cancerologie Thoracique |
| Drug class | Nucleoside analog antimetabolite |
| Target | Ribonucleotide reductase; DNA polymerase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Gemcitabine is a deoxycytidine analog that is phosphorylated intracellularly to its active triphosphate form. It inhibits ribonucleotide reductase, reducing deoxyribonucleotide pools, and is incorporated into DNA during replication, leading to chain termination and apoptosis. It is particularly effective against rapidly dividing cells.
Approved indications
- Non-small cell lung cancer
- Pancreatic cancer
- Bladder cancer
- Breast cancer
- Ovarian cancer
Common side effects
- Myelosuppression (neutropenia, thrombocytopenia, anemia)
- Nausea and vomiting
- Fatigue
- Rash
- Elevated liver enzymes
- Dyspnea
- Hemolytic uremic syndrome (rare)
Key clinical trials
- Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial (PHASE2)
- Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer (PHASE3)
- MP0317 in Combination With Chemoimmunotherapy in First Line Treatment for Patients With Advanced Biliary Tract Carcinoma (PHASE2)
- Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma (PHASE2)
- Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (PHASE2)
- Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs) (PHASE3)
- Neoadjuvant Chemotherapy Before Surgery vs Surgery Alone for UTUC: A Randomized Trial (PHASE2)
- Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gemcitabine alone CI brief — competitive landscape report
- Gemcitabine alone updates RSS · CI watch RSS
- Intergroupe Francophone de Cancerologie Thoracique portfolio CI